Article info
PDFOriginal research
Clinical validation of qPCR Target Selector™ assays using highly specific switch-blockers for rare mutation detection
- Correspondence to Dr Veena Singh, Clinical Laboratory, Biocept Inc, San Diego, California, USA; vsingh{at}biocept.com
Citation
Clinical validation of qPCR Target Selector™ assays using highly specific switch-blockers for rare mutation detection
Publication history
- Received December 19, 2019
- Revised January 23, 2020
- Accepted February 4, 2020
- First published March 4, 2020.
Online issue publication
December 21, 2020
Article Versions
- Previous version (18 September 2020).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ.